Full Access Saves as Much as $11,960 per Patient vs Current Restricted Access
Newswise — Princeton, NJ—June 27, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the publication of an empirical study demonstrating that current Medicaid policies restricting hepatitis C treatment to patients with advanced disease are more costly and less effective than unrestricted, full-access strategies. The results of this novel research, “Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients,” were published in the June 2016 issue of Value in Health.
The authors used a Markov model to compare two strategies for 45-55 year old Medicaid beneficiaries: (1) Current Practice—only advanced disease is treated before Medicare eligibility; and (2) Full Access—both early-stage and advanced disease are treated before Medicare eligibility. Full Access was less costly and more effective than Current Practice for all cohorts and perspectives, with differences in cost ranging from $5,369 to $11,960 and in effectiveness from 0.82 to 3.01 quality-adjusted life-years. Compared with Current Practice, Full Access averted 5,994 hepatocellular carcinoma cases and 121 liver transplants per 100,000 patients.